New Prescription Migraine Drugs Aren’t Resonating with Patients—Here’s How Pharma Can Boost Uptake
PM360
JUNE 29, 2022
However, patient uptake hasn’t matched rising market competition. And among patients who have tried preventive medications for migraine, 39% said they no longer took them. These low adoption rates highlight the need for more migraine-drug awareness and suggest that pharma marketers should explore new strategies to boost patient uptake.
Let's personalize your content